Iambic Presents Updated IAM1363 Clinical Data at ESMO 2026, Showing Durable Responses with a Favorable Tolerability Profile in Heavily Pretreated Participants with HER2-Driven Cancers
Iambic official newsroom · Indexed industry source record · Source published: Mon Oct 26 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · Indexed here: Mon Oct 26 2026 12:07:42 GMT+0000 (Coordinated Universal Time)
Saved source excerpt
IAM1363, now in a Phase 1/1b stud y , was designed using Iambic’s molecular superintelligence platform and brought to clinic al development in approximately two years D ata presented at ESMO 2026 demonstrates IAM1363 was well tolerated with low rates of Grade 3 or higher treatment-related adverse events, serious adverse events , and dose modifications M ore than half of participants dosed at 960 m
This is a cited excerpt from the source. Read the original link for the complete text. Automated indexing and topic classification do not constitute fact verification.